1129541-56-5Relevant academic research and scientific papers
UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM
-
Page/Page column 115, (2019/12/25)
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depression, a neurodegener
GLUCAGON RECEPTOR MODULATORS
-
Page/Page column 27, (2012/08/27)
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS
-
Page/Page column 109; 110, (2009/04/25)
The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.
